Ivor Caro

4.0k citations

65 papers · 2.2k indexed · h-index 25

Impact in

Dermatology top 0.5%
- Dermatology and Skin Diseases
- Cancer and Skin Lesions
Immunology top 5%
- Psoriasis: Treatment and Pathogenesis

Papers in

Dermatology 22
- Dermatology and Skin Diseases 7
Immunology 19
- Psoriasis: Treatment and Pathogenesis 19

Co-authors: Loren E. Golitz Patti Stampone Mary Owens John K. Geisse Jane S. Lindholm Alice B. Gottlieb Kenneth B. Gordon Kim Papp
Journals: Journal of the American Academy of Dermatology (14 papers)Clinical Cancer Research (4 papers)Annals of Oncology (4 papers)Dermatology (4 papers)Journal of Cutaneous Medicine and Surgery (3 papers)
Partner nations: United States Canada Australia

In The Last Decade

Ivor Caro

65 papers receiving 2.1k citations

Peers

Countries citing papers authored by Ivor Caro

Since Specialization

Citations

This map shows the geographic impact of Ivor Caro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivor Caro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivor Caro more than expected).

Fields of papers citing papers by Ivor Caro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivor Caro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivor Caro. The network helps show where Ivor Caro may publish in the future.

Co-authors

The 25 scholars most cited alongside Ivor Caro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ivor Caro Line = papers co-authored together Ivor Caro links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study ESMO Open ·Eric J. Sherman, J.L. Lee, Philip R. Debruyne, Bhumsuk Keam, Sang Joon Shin, Ann Gramza, Ivor Caro, Reena Amin, Kunal Shah, Y. Yan, Robert Huddart, Thomas Powles	2023	11
2	Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF V600-mutated Metastatic Melanoma Clinical Cancer Research ·Yibing Yan, Matthew Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Koeppen, Jessie J. Hsu, Ilsung Chang, Ivor Caro, Isabelle Rooney, Grant A. McArthur, Antoni Ribas	2019	27
3	Vismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application. PubMed ·Jennifer Tang, C. William Hanke, Ivor Caro	2018	3
4	Vismodegib Use in Clinical Practice: Analysis of a United States Medical Claims Database. PubMed ·C. William Hanke, Shivani K. Mhatre, David Oliveri, Marko Zivkovic, Ivor Caro, Daniel Bergström, Keith Dawson, Camelia S. Sima	2018	2
5	Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib Clinical Cancer Research ·Matthew Wongchenko, Grant A. McArthur, Brigitte Dréno, James Larkin, Paolo A. Ascierto, Jeffrey A. Sosman, Luc Andries, Mark Kockx, Stephen D. Hurst, Ivor Caro, Isabelle Rooney, Priti S. Hegde, Luciana Molinero, Huibin Yue, Ilsung Chang, Lukas C. Amler, Yibing Yan, Antoni Ribas	2017	28
6	Carcinogenicity assessment of the Hedgehog pathway inhibitor, vismodegib in Tg.rasH2 mice and Sprague-Dawley rats Regulatory Toxicology and Pharmacology ·Jinze Li, Eric J. Morinello, Thomas Larsen, Denzil F. Frost, Ivor Caro, Stephen E. Gould, Lisa Wong, Angela Hendricks, Noël Dybdal, Donna M. Dambach, Melissa M. Schutten	2017	2
7	Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib Journal of the American Academy of Dermatology ·Tina Bhutani, Michael Abrouk, Camelia S. Sima, Natalia Sadetsky, Jeannie Hou, Ivor Caro, Mary‐Margaret Chren, Sarah T. Arron	2017	52
8	Impact of key prognostic factors on long-term overall survival in BRAFV600-mutated metastatic melanoma patients treated with vemurafenib in the BRIM-3 study Melanoma Research ·Axel Hauschild, Paul B. Chapman, Caroline Robert, James Larkin, J.B.A.G. Haanen, A. Ribas, David Hogg, Omid Hamid, P.A. Ascierto, Alberto Testori, Paul Lorigan, R. Dummer, J. A. Sosman, Keith T. Flaherty, Matthew Wongchenko, Yuchun Yan, I‐Fen Chang, S. Coleman, Ivor Caro, Grant A. McArthur	2016	2
9	A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma Journal of the American Academy of Dermatology ·Howard Sofen, Kenneth G. Gross, Leonard H. Goldberg, Harry H. Sharata, Tiffani K. Hamilton, Barbara M. Egbert, Benjamin Lyons, Jeannie Hou, Ivor Caro	2015	56
10	Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened Clinical Cancer Research ·Tracy Tang, Jean Y. Tang, Dongwei Li, Mike Reich, Christopher A. Callahan, Ling Fu, Robert L. Yauch, Frank Wang, Karen Kotkow, Kris S. Chang, Elana Shpall, Angela Ruohao Wu, Lee L. Rubin, James C. Marsters, Ervin H. Epstein, Ivor Caro, Frédéric J. de Sauvage	2011	53
11	Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome SHILAP Revista de lepidopterología ·Glen J. Weiss, Raoul Tibes, Lisa Blaydorn, Gayle Jameson, Molly Downhour, Erica White, Ivor Caro, Daniel D. Von Hoff	2011	4
12	The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment Clinical Cancer Research ·Ivor Caro, Jennifer A. Low	2010	88
13	Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial International Journal of Dermatology ·Kim Papp, Reni Bressinck, Scott Fretzin, Bernard S. Goffe, Steven Kempers, Kenneth B. Gordon, Ivor Caro, Patricia A. Walicke, Xiaolin Wang, Alan Menter, (unknown)	2006	55
14	Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial Journal of the American Academy of Dermatology ·Alice B. Gottlieb, Tiffani K. Hamilton, Ivor Caro, Paul Kwon, Peter G. Compton, Craig L. Leonardi	2006	65
15	Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis Journal of the American Academy of Dermatology ·Kim Papp, Bruce Miller, Kenneth B. Gordon, Ivor Caro, Paul Kwon, Peter G. Compton, Craig L. Leonardi	2006	30
16	Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II Journal of Cutaneous Medicine and Surgery ·Kim Papp, Charles Camisa, Stephen Stone, Ivor Caro, Xiaolin Wang, Peter G. Compton, Patricia A. Walicke, Alice B. Gottlieb	2005	7
17	Incidence of infection during efalizumab therapy for psoriasis: Analysis of the clinical trial experience Clinical Therapeutics ·Richard G. Langley, Wayne P. Carey, Elyse S. Rafal, Stephen K. Tyring, Ivor Caro, Xiaolin Wang, Graham Wetherill, Kenneth B. Gordon	2005	36
18	Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies Journal of the American Academy of Dermatology ·John K. Geisse, Ivor Caro, Jane S. Lindholm, Loren E. Golitz, Patti Stampone, Mary Owens	2004	364
19	Case 5-2003 New England Journal of Medicine ·Ivor Caro, Artur Zembowicz	2003	2
20	Leucomelanoderma in blacks South African Medical Journal ·M Dogliotti, Ivor Caro, R. Hartdegen, David A. Whiting	1974	4

About Ivor Caro

Ivor Caro is a scholar working on Dermatology, Immunology, Small Animals, Oncology and Pathology and Forensic Medicine, having authored 65 papers that have together received 2.2k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (19 papers), Melanoma and MAPK Pathways (14 papers), Hedgehog Signaling Pathway Studies (9 papers), Cutaneous Melanoma Detection and Management (7 papers), Dermatology and Skin Diseases (7 papers), Autoimmune Bullous Skin Diseases (7 papers), Nonmelanoma Skin Cancer Studies (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). The work is most often cited by research in Dermatology (813 citations), Immunology (836 citations), Oncology (572 citations), Immunology and Allergy (119 citations) and Pathology and Forensic Medicine (316 citations). Ivor Caro has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Loren E. Golitz, Patti Stampone, Mary Owens, John K. Geisse, Jane S. Lindholm, Alice B. Gottlieb, Kenneth B. Gordon, Kim Papp, Craig L. Leonardi and Jennifer A. Low. Their work appears in journals such as Journal of the American Academy of Dermatology, Clinical Cancer Research, Annals of Oncology, Dermatology and Journal of Cutaneous Medicine and Surgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact